Consider these steps for pharmacists to further evolve their role as the pandemic continues to put pressure on the health care system.
An automated reinforcement platform was shown to increase statin adherence by 34.6%.
The oncology pharmaceutical market is rapidly growing and changing.
As Pharmacy Times® goes to press this month, there is a lot of encouraging news on the coronavirus 2019 (COVID-19) front.
The perception and utilization of OTC medications among primary care providers for gastroesophageal reflux disease and chronic constipation shows a need for improved patient education on these medications.
Examination of changes in utilization, dose adequacy, and duration associated with market entry of the oral chelator deferasirox as a potential substitute for parenteral deferoxamine.
The increasing prevalence of oral oncolytics use, further accelerated by COVID-19, heightens the need for strong patient-pharmacist treatment coordination.
Adherence for targeted therapies is even more essential now than it ever has been. This case study of services offered at a specialty pharmacy illustrates the impact of hepatitis C patients.
Adherence to risperidone long-acting injection (RLAI) therapy in the outpatient setting was poor. Degree of discharge planning from inpatient hospitalization was not associated with RLAI adherence.
As we shift the healthcare paradigm, new ways to lower costs and improve adherence are worth another look.
Among the commercially insured, pharmacy benefits define the availability, accessibility, and cost of prescription drugs.
Therapeutic interchange from donepezil to galantamine extended-release: a 3-month analysis.
Retina Risk is a new app that patients can use to help screen for their risk of retinopathy.
The authors examined trends in the utilization of prescription opioid medication following introduction of abuse deterrent technology for Oxycontin.
The ability of manufacturers to convey the efficacy and safety of a new biosimilar is crucial.
Eravacycline, Omadacycline, Plazomicin, and a Rifamycin Add to the Armamentarium for Treating Resistant Infections
As 2018 signals the end of the patent cliff and branded generics face tougher competition from nonbranded manufacturers, companies are diversifying their portfolios and focusing on innovation to ensure long-term viability.
There is a constant balancing act for health care systems to provide the newest and most up-to-date care for patients while being financially responsible.
We examined the prevalence of use and cost impact of DPP-4 inhibitors and GLP-1 receptor agonists in people with diabetes.
Major patient and professional advocacy organizations discussed factors leading to patient nonadherence to prescription therapy and solutions for overcoming the major barriers.
The Agency Sees Potential in Generic Competition to Reduce Drug Costs for Patients With Diabetes
Pharmacists can assist with advising patients who present with quality concerns to use CBD products that provide certificates of analyses, and catch significant drug interactions before they occur.
Pharmacists can use sound advice and practical foot care tips to help patients avert dangerous foot infections.